Roche Holding AG

RHHVF · SWISS

$475.00+$16.91 (+3.69%)TodayMarket closed · Oct 20, 3:58 PM ET

Prev close $458.09

Latest news

NewsJul 15, 1:46 AM ET
FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus
NewsMay 1, 10:29 AM ETMighty Wisdom
Where Roche Fits In A 2026 Portfolio
NewsApr 22, 2:59 AM ET
Reported Earlier, Genentech's Fenebrutinib Reduces Relapses By Up To 58.5% Versus Teriflunomide In Phase III FENhance 1 And 2 Relapsing Multiple Sclerosis Studies
Press releaseMar 5, 1:15 AM ETPRNewswire
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
NewsMar 2, 1:17 AM ET
Roche's Fenebrutinib Poised To Become First Oral Brain-Penetrant Treatment For Both RMS And PPMS After FENhance 1 Meets Primary Endpoint
NewsFeb 9, 3:38 AM ET
Reported Saturday, Roche Reports Phase III FENtrepid ACTRIMS Data Showing Investigational Fenebrutinib Meets Non-Inferiority Vs Ocrevus And Reduces Disability Progression In PPMS
NewsJan 29, 1:48 AM ET
Roche Guides To Mid Single-Digit Sales Growth And High Single-Digit Core EPS Expansion In 2026
NewsNov 10, 1:36 AM ET
Roche's Fenebrutinib Delivers Dual Advances Across RMS And PPMS Showing Significant Relapse Reduction And Disability Slowdown Versus Standard Therapies
NewsOct 23, 1:43 AM ET
Roche Reports 7% CER Sales Growth To CHF 45.9B In First Nine Months 2025, Raises Full-Year Earnings Outlook And Expects High Single To Low Double Digit EPS Growth
NewsJul 24, 1:57 AM ET
Roche H1 2025 Sales CHF 30.944B Up From CHF 29.848B YoY, Core EPS CHF 11.08 Up From CHF 10.23 YoY
NewsJan 30, 3:05 AM ET
Roche For 2025 Expects Mid-Single-Digit Sales Growth And High-Single-Digit Core EPS Growth

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus

Where Roche Fits In A 2026 Portfolio

Reported Earlier, Genentech's Fenebrutinib Reduces Relapses By Up To 58.5% Versus Teriflunomide In Phase III FENhance 1 And 2 Relapsing Multiple Sclerosis Studies

New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools

Roche's Fenebrutinib Poised To Become First Oral Brain-Penetrant Treatment For Both RMS And PPMS After FENhance 1 Meets Primary Endpoint

Reported Saturday, Roche Reports Phase III FENtrepid ACTRIMS Data Showing Investigational Fenebrutinib Meets Non-Inferiority Vs Ocrevus And Reduces Disability Progression In PPMS

Roche Guides To Mid Single-Digit Sales Growth And High Single-Digit Core EPS Expansion In 2026

Roche's Fenebrutinib Delivers Dual Advances Across RMS And PPMS Showing Significant Relapse Reduction And Disability Slowdown Versus Standard Therapies

Roche Reports 7% CER Sales Growth To CHF 45.9B In First Nine Months 2025, Raises Full-Year Earnings Outlook And Expects High Single To Low Double Digit EPS Growth

Roche H1 2025 Sales CHF 30.944B Up From CHF 29.848B YoY, Core EPS CHF 11.08 Up From CHF 10.23 YoY

Roche For 2025 Expects Mid-Single-Digit Sales Growth And High-Single-Digit Core EPS Growth